Stealth: FDA misses approval deadline for biotech's rare disease drug
The delay for Stealth Biotherapeutics comes amid a heightened focus on the impact FDA job cuts might have on drug reviews.
Read full article »
Stealth is a Massachusetts-based biopharmaceutical company that develops and commercializes therapies for the treatment of mitochondrial dysfunctions.
Read more